Comparison of Iron(III)-Trans-1,4-Diaminocyclohexane-tCDTA and Iron(III)-Trans-1,4-Diaminocyclohexane-tCDTA-Dimer With Gadobutrol for T1 Contrast Enhancement in DCE-MRI

[Fe( trans-Di-t CDTA)] provided comparable contrast enhancement and kinetics to gadobutrol at the same molecular dose (double the metal dose), is very stable, and could serve as an alternative to nonspecific GBCA, thereby avoiding potential long-term gadolinium toxicity and retention concerns as well as environmental gadolinium deposition. [Fe( trans-t CDTA)] + required a higher dose and showed delayed clearance in blood and other organs.